national medical research center for hematology

• ASH Foundation
• Log in or create an account
• Publications
• Diversity Equity and Inclusion
• Global Initiatives

Welcome to ASH!

The American Society of Hematology (ASH) is the world’s largest professional society of clinicians and scientists who are dedicated to conquering blood diseases. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.

Explore the ASH Annual Meeting

Landing Page

Help ASH Identify "New Blood"

2023 ASH Annual Report

Call for Editor Nominations

ASH Academy On Demand

The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.

View More ASH Research

The American Society of Hematology offers a wide array of educational products and services for clinicians and scientists at any stage in their careers.

For Clinicians

For trainees, for educators, for patients.

View More ASH Education

PUBLICATIONS

ASH publications include both clinical and scientific research, and education in the field of hematology.

The Blood Journals are the premier scholarly resource for hematologists worldwide. Since the founding of Blood in 1946, the Blood Journals have been a trusted source for basic, translational, and clinical research. Each journal is led by an editorial team of active scientists and clinicians who are top experts in their area.

The Hematologist: ASH News and Reports , the American Society of Hematology’s member newsletter, is designed for the broad constituency of ASH, ranging from basic scientists to practicing clinicians, all working toward the ultimate goal of conquering blood diseases.

ASH Clinical News , a monthly news magazine specifically designed to appeal to clinical practitioners in hematology and oncology, provides timely updates in the field by reporting on key medical meetings, clinical trials, innovative technology, and influential papers in the literature.

View All Publications

GET INVOLVED

ASH is always looking for ways to better serve all communities of clinicians and scientists working to conquer blood disease worldwide. Whether you are looking to take action by being an advocate for hematology, support the foundation through donation, or joining a diverse community of more than 17,000 hematologists, you will help conquer blood diseases worldwide.

Every gift to the ASH Foundation is a vital philanthropic investment in ASH’s mission of helping hematologists conquer blood diseases worldwide. Donations of all amounts help sustain the future of hematology as a vibrant, flourishing career path in both academia and clinical practice.

Learn About ASH Global Initiatives

ASH FAMILY OF SITES

ASH Publications

ASH Pocket Guides

ASH Job Center

ASH Image Bank

ASH provides the most current practice tools, clinical support, and educational products in hematology that you need for every stage of your career. Our family of sites, developed by subject-matter experts, are designed to help physicians improve their medical knowledge, engage in quality activities, meet and learn from thousands of hematologists worldwide and continue to help conquer blood diseases worldwide.

Learn More about ASH

National Cancer Institute - Cancer.gov

NIH Hematology Oncology Fellowship

Training the next generation of clinicians and physician-scientists

How to Apply

Program details, meet our people.

The mission of the National Institutes of Health (NIH) Hematology Oncology Fellowship is to use the unique clinical and basic research resources of the NIH to advance the diagnosis, treatment, and prevention of hematologic and oncologic diseases by developing and training the next generation of clinicians and physician scientists. This program is jointly sponsored by the National Cancer Institute and National Heart, Lung, and Blood Institute.

View a version of this video with extended audio descriptions .

Top 10 Reasons to Do A Hematology Oncology Fellowship at NIH

• Unparalleled opportunity to work alongside and be mentored by top scientists and clinicians in cutting-edge research across the scientific spectrum, including basic science, cancer prevention, drug development, and clinical trials, such as the ones described in the Discovery Channel documentary made at the NIH, First in Human .  Research is the antidote to burnout - no contest.
• Opportunity to train at world’s largest hospital dedicated to clinical research, alongside co-fellows from a broad range of backgrounds and experiences, with medical training completed all over the world, and with diverse career goals and interests.  Training includes exceptional clinical rotations, dedicated time for didactics - every Friday! - quality improvement initiatives, and TRULY protected time for research. 
• Mentorship starting day 1 from program leadership and faculty who are  dedicated  to the NIH mission to attract “the most brilliant and promising clinical fellows from the United States and abroad.”  Passion, but not experience, required!  Despite being a large program, the program is close-knit and hands-on, with program leadership focused on fostering each fellow's professional growth, wellness, and work-life balance.
• Integration of clinical rotations at top area hospitals, including Georgetown, Johns Hopkins University and University of Maryland, to broaden fellows’ clinical training and exposure to standard of care and various academic institutions.
• Outstanding compensation, including salary, the ability to moonlight, and paid relocation.
• Non-competitive  student  loan repayment program  for eligible fellows (YES - you can get your student loans repaid as a fellow!)
• Formal partnerships with government regulatory agencies, including  FDA  and  CTEP  - including opportunities to train at the FDA during your research years through the NCI-FDA Interagency Oncology Task Force  NCI-FDA IOTF .  Ability to earn an MPH through the  Cancer Prevention Fellowship Program  track.  Ability to earn dual training in Hematology and Transfusion Medicine, with unparalleled opportunity to train within the NIH's own  Blood Bank .
• Exceptional resources to support scholarly activity and research endeavors, including travel to national meetings, workshops, fellows' forums, grant writing resources, the Foundation for the Advanced Education in the Sciences  FAES - the NIH "University" , etc.
• Numerous social events - including research, career development and team-building retreats - outdoor activities, and cultural amenities in the beautiful Washington, D.C. area.  
• Above all, the honor of caring for amazing, diverse patients from all over the U.S. and the world who come to the NIH hoping for a chance at therapies that might help themselves and others.

The storied history of medical hematology and oncology fellows at the National Institutes of Health (NIH) dates back more than 80 years. Read more...

Physicians who have completed their residency in internal medicine can apply to the program yearly, starting on July 1 .

We provide a strong clinical grounding in hematology and oncology as well as exposure to clinical, laboratory and translational research.

Our leadership and faculty include inspiring and award-winning educators and mentors.

The National Institutes of Health Clinical Center is among the world’s top cancer research facilities, where many important therapies have been pioneered, including CAR T-cell therapy and other immunotherapy approaches that use adoptive cell transfer. NIH is also involved in efforts to determine the most efficient and effective ways to evaluate new anticancer therapies, such as developing new clinical trial designs for precision medicine and immunotherapies.

The Hematology Oncology Fellowship program builds on NCI’s 50-plus-year involvement in cancer research linked to the discovery and development of approximately half of the chemotherapeutic drugs currently used by oncologists to treat cancer. Fellows also benefit from the extensive body of research conducted in benign hematology and hematologic malignancies within the National Heart Lung and Blood Institute. Learn more about NCI’s Center for Cancer Research  advances  and  landmarks  throughout the years.

Fellows are able to participate in the more than 350 clinical trials in  oncology  and  hematology  taking place at NIH, and they are able to serve as principal and/or associate investigators throughout their fellowships.

Fellows working with clinical teams have the opportunity to help design, write, and run clinical trials, and then analyze and publish their findings.

Productivity and PIs

The Hematology Oncology Fellowship is part of the National Institutes of Health’s intramural research program, as are the dozens of  principal investigators  that fellows can collaborate with during their time in the program.  Our fellows regularly publish papers and present posters, and they also have a good track record for making oral presentations and receiving grants.

We offer several lecture series, inpatient walk rounds, tumor board reviews, a journal club and more.

An official website of the United States government

Here’s how you know

Official websites use .gov A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS A lock ( A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

• Heart-Healthy Living
• High Blood Pressure
• Sickle Cell Disease
• Sleep Apnea
• Information & Resources on COVID-19
• The Heart Truth®
• Learn More Breathe Better®
• Blood Diseases and Disorders Education Program
• Publications and Resources
• Blood Disorders and Blood Safety
• Sleep Science and Sleep Disorders
• Lung Diseases
• Health Disparities and Inequities
• Heart and Vascular Diseases
• Precision Medicine Activities
• Obesity, Nutrition, and Physical Activity
• Population and Epidemiology Studies
• Women’s Health
• Research Topics
• Clinical Trials
• All Science A-Z
• Grants and Training Home
• Policies and Guidelines
• Funding Opportunities and Contacts
• Training and Career Development
• Email Alerts
• NHLBI in the Press
• Research Features
• Past Events
• Upcoming Events
• Mission and Strategic Vision
• Divisions, Offices and Centers
• Advisory Committees
• Budget and Legislative Information
• Jobs and Working at the NHLBI
• Contact and FAQs
• NIH Sleep Research Plan
• About the NHLBI
• < Back To Division of Intramural Research

Hematology Branch

Neal young, m.d., branch chief.

Investigators in the Hematology Branch (HB) study normal and abnormal hematopoiesis—the development and differentiation of stem cells into multiple types of blood cells—in the clinic and in the research laboratory. Patients who have a variety of bone marrow failure syndromes and acute and chronic leukemias attend the HB’s clinic and may be enrolled in clinical research protocols at the NIH Clinical Center. Interventions are intended to reverse marrow failure, cure or ameliorate leukemias by stem cell transplant, and control lymphoproliferative diseases such as chronic lymphocytic leukemia by drug therapy. In the laboratory, basic cellular and molecular biology, immunologic, and genomic techniques and approaches are used to study patient samples, cells, cell lines, and in animal models. The Branch has been an international leader in developing understanding of the pathophysiology of hematologic diseases and improving their outcomes.

Hematopoiesis and Bone Marrow Failure

Research in the Hematopoiesis and Bone Marrow Failure Laboratory, led by Dr. Neal Young, spans the basic sciences, clinical trials, and epidemiology. Bench work involves methods of cell and molecular biology, immunology, and virology. Blood cell production in healthy individuals and especially in patients with bone marrow failure is the main theme. Advanced techniques most recently include single cell RNAseq, CRISPR-Cas9 gene editing, multicolored bar coded flow cytometry, and SomaLogic deep proteomics.

• Senior Investigator
• [email protected]

Lymphoid Malignancies

The Laboratory of Lymphoid Malignancies, led by Dr. Adrian Wiestner, aims to improve the treatment of patients with chronic lymphocytic leukemia (CLL). The group combines clinical and laboratory investigations to identify the molecular drivers of the disease. These insights are translated into clinical trials that seek to selectively eliminate tumor cells using targeted therapy. CLL samples donated by patients participating in these clinical trials are in turn used in the laboratory to study the effectiveness of the treatment and the reaction of the tumor cells to drugs, which can provide insights how to further improve the therapy.

• Adrian Wiestner
• M.D., Ph.D.
• [email protected]

• Medical Departments & Centers

Expertise and rankings

Mayo Clinic hematologists are recognized as experts in the field of blood diseases.

Hematologists at Mayo Clinic are consistently recognized by external organizations for providing outstanding patient care. These endorsements reinforce our commitment to providing expert, whole-person care to everyone who needs healing.

As part of their commitment to treating blood disorders, Mayo Clinic hematologists serve as expert advisers on numerous treatment guideline panels for the National Comprehensive Cancer Network and other organizations at the forefront of blood cancers such as the Lymphoma Research Foundation, International Myeloma Working Group, International Waldenstrom Macroglobulinemia Foundation, International Society of Amyloidosis and the Leukemia and Lymphoma Society, among many others.

Nationally recognized expertise

Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, are ranked among the Best Hospitals for cancer by U.S. News & World Report. Mayo Clinic in Rochester, Minnesota, is ranked as the top hospital in Minnesota, Mayo Clinic in Phoenix/Scottsdale, Arizona, is ranked as the top hospital in Arizona, and Mayo Clinic in Jacksonville, Florida, is ranked the top hospital in Florida.

The Mayo Clinic Comprehensive Cancer Center has held its National Cancer Institute (NCI) cancer center designation since 1973. As a comprehensive cancer center, Mayo Clinic has met NCI's more-rigorous standards that include:

• Basic laboratory research
• Participation in high-priority NCI clinical studies
• Applied and clinical research
• Cancer prevention and control programs
• Education and training of health care professionals
• Public information services
• Community service and outreach

The NCI recognizes nine formal programs to the Mayo Clinic Comprehensive Cancer Center, comprising:

• Cancer immunology and immunotherapy
• Cell biology
• Experimental therapeutics
• Gastrointestinal cancer
• Gene and virus therapy
• Hematologic malignancies
• Neuro-oncology
• Population sciences
• Women's cancer

Mayo Clinic's CAR -T Cell Programs at campuses in Arizona, Florida and Minnesota are also accredited by the Foundation for Accreditation of Cellular Therapy. The foundation sets international standards to ensure cellular therapies are high quality.

Mayo Clinic's campus in Florida is one of four sites in Florida to receive the Cancer Center of Excellence Designation from the state of Florida. This designation recognizes providers that demonstrate excellence in patient-centered coordinated care for people undergoing cancer treatment in Florida.

Expertise for a new era of medicine

By harnessing expertise from a wide array of specialties and scientific disciplines, Mayo Clinic's hybrid centers translate the latest medical research into real-life options for patients.

• Mayo Clinic's Center for Individualized Medicine  focuses on the genomic, molecular and cellular basis of diseases to provide the exact care you need at the time you need it.
• Mayo Clinic's Center for Regenerative Biotherapeutics pioneers new approaches to develop next-generation reparative solutions.
• Mayo Clinic's Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery  combines innovation, continuous improvement, implementation science and research-quality methodologies to improve health care delivery.
• Department home
• Tests & procedures
• Conditions treated
• Specialty groups
• Expertise & rankings
• Locations, travel & lodging
• Clinical trials
• Patient stories
• Costs & insurance
• News from Mayo Clinic
• Request an Appointment

Make twice the impact

Your gift can go twice as far to advance cancer research and care!

• UNC Chapel Hill

The Division of Hematology offers expertise in the diagnosis and treatment of a broad spectrum of blood disorders. Hematology faculty participate in specialized patient care and research programs in the areas of hematologic malignancies, thrombosis, bleeding disorders, sickle cell anemia, and bone marrow transplantation. Specialized interdisciplinary hematology clinics and conferences are held weekly in the areas of benign and malignant hematology, in association with other members of the UNC Blood Research Center, nationally recognized in the areas of Hemostasis and Thrombosis, Hemophilia, and the UNC Lineberger Comprehensive Cancer Center, one of the foremost cancer research centers in the country. The UNC Blood Research Center, UNC Lineberger, and the UNC Sickle Cell Program, are central to implementing the patient care and research missions of the Division.

Focus Areas

Each of our Division’s subspecialty research groups are recognized as leading programs of national and regional distinction. Click below to learn more about particular focus areas.

The thrombosis program at UNC is focused on innovative clinical practice models.  In 2021, the newly developed rapid follow-up DVT clinic provided care to 130 patients from across the state, improving access to urgent specialized care in thrombosis.  Dr. Stephan Moll’s multidisciplinary Athlete Thrombosis Program. The “UNC Athletes and Blood Clots Program” offers state-of-the art multispecialty medical care (Hematology plus Sports Medicine) to high level athletes who have had a deep vein thrombosis (DVT or pulmonary embolism (PE).

The UNC Sickle Cell Clinical Program is a founding member of the GRNDaD registry for people with sickle cell disease, which is prospective and multi-site. We communicate regularly with state educators, and we are working diligently to care for our patients who are many miles away, often down the coast, for whom regular care is difficult.  We participate in UNC-originated and multi-site research studies, working to find new ways to manage and treat sickle cell disease.

Learn more on the UNC Blood Research Center website. Bone Marrow Transplant Program

The UNC Bone Marrow Transplant and Cellular Therapy (BMTCT) Program cares for both adults and children with hematologic malignancies and solid tumors at the NC Cancer Hospital. The program has a long history of basic and translational research with 4 NIH/CDC funded investigators, as well as clinic al trials and investigations. Areas of focus for the program include:

Basic and translational research :

Health optimization and patient reported outcomes research

Management of post-transplant complications.

Disease relapse as well as infections and graft versus host disease remain the leading causes of post-transplant mortality. Multiple investigators are involved in clinical research aimed at addressing these issues.

Learn more on the  Bone Marrow Transplant and Cellular Therapy  website.

The Leukemia Program has a robust clinical research program focused on investigating novel therapies for patients with acute leukemia, myelodysplastic syndromes, myeloproliferative neoplasms and chronic leukemia’s. Highlights of our research group include:

• Joshua Zeidner, MD is leading several innovative clinical trials exploring new ways to treat newly diagnosed AML. He is leading a multi-institutional randomized phase 2 clinical trial of CPX-351 versus CPX-351 + pomalidomide (NCI-10434; NCT04802161 ) in newly diagnosed AML with myelodysplasia-related changes (AML-MRC) , a high-risk subset of AML patients with suboptimal clinical outcomes.
• Dr. Zeidner is also leading a multi-institutional phase 2 clinical trial exploring Tagraxofusp (Antibody-drug conjugate to CD123) in newly diagnosed secondary AML patients ( NCT05442216). This innovative clinical trial is the first to investigate novel treatment options for AML patients with previous treatment with hypomethylating agents.
• University of North Carolina is an active site on the Beat AML  initiative ( NCT03013998) , a multi-institutional precision-medicine based clinical trial sponsored by the Leukemia and Lymphoma Society. Beat AML conducts a comprehensive centralized genomic profile of a patient’s AML. Investigational treatment regimens are thereby selected based on each individual unique genomic profile.  
• We are participating in clinical trials targeting specific genomic subpopulations of AML that do not respond favorably to conventional chemotherapy regimens. For example, Dr. Zeidner is the Principal Investigator of a randomized phase 3 study of azacitidine plus magrolimab (anti-CD47) versus physician choice in newly diagnosed AML with TP53 mutations (ENHANCE-2: NCT04778397)  Relapsed/Refractory AML
• We have a multitude of novel clinical trial options for patients with relapsed/refractory AML including targeted therapies and investigational strategies for unique subgroups of AML
• Daniel Richardson, MD’s research focuses on developing and advancing methods to assess patient values, goals, and preferences to improve treatment decision-making. His group has developed several instruments to quantify the treatment outcome preferences of patients with blood cancers and has several trials evaluating the clinical implementation of these instruments to better align treatment decisions to what matters most to patients.
• We are interested in exploring novel treatment approaches for patients with low and high-risk MDS. Dr. Zeidner is the Principal Investigator of an industry-sponsored randomized phase 3 study investigating the combination of azacitidine plus magrolimab (CD47 antibody) versus azacitidine plus placebo for newly diagnosed high-risk MDS (ENHANCE: NCT04313881)
• University of North Carolina is a national leader in innovative immunotherapy approaches in ALL. 
• Brandi Reeves, MD leads the MPN Program and serves as Co-PI for the UNC Lineberger MDS Foundation Center of Excellence. Her research focuses on understanding mechanisms of thrombosis in MPN’s and utilizes a bench-to-bedside approach wherein observations gleaned from the clinic are taken to the laboratory with the ultimate goal of translating back to the clinic to improve patient care.
• We have a multitude of cutting-edge clinical trial options for patients with newly diagnosed and relapsed/refractory CLL.

1. Lymphoma in elderly or frail patients.

• The lymphoma group has focused on several projects that specifically target effective treatment approaches in elderly or frail patients. Anne Beaven, MD is leading a study (S1918) evaluating oral azacitidine with R-miniCHOP for the treatment of DLBCL in patients over the age of 75. Christopher Dittus, DO, MPH,  is collaborating with Levine Cancer Center to study the effectiveness of nivolumab consolidation in primary CNS lymphoma patients over the age of 65 who are not candidates for stem cell transplant or radiation.
• Additionally, Dr. Christopher Dittus, has an investigator-initiated trial (IIT) evaluating the targeted BTK inhibitor, acalabrutinib for the treatment of relapsed primary and secondary CNS lymphoma (LCCC1841). This study targets patients who are not eligible for more intensive chemotherapy options.

2. Virally-mediated lymphomas.

• Christopher Dittus, DO, MPH is leading a multicenter IIT evaluating the antibody-drug conjugate brentuximab vedotin for the treatment of the rare adult T-cell leukemia/lymphoma (LCCC1637).
• UNC is the only active AIDS Malignancy Consortium (AMC) site in North Carolina . We currently have several prospective studies open.

3. CAR-T cell therapy

• Most of the clinical CAR-T research has been led by Natalie Grover, MD in the lymphoma group. Areas of specific focus in lymphoma have been the CD30 CAR-T program, kappa CAR-T clinical trial for kappa expressing lymphomas, and the CD19 CAR-T trial using the inducible caspase 9 safety switch (LCCC1813) which has accrued CD19+ patients including Waldenstrom’s Macroglobulinemia.
• CD30 Program: This has led to a publication in JCO. This product has also received FDA RMAT (regenerative medicine advanced therapy) designation. We now have trials open in Hodgkin lymphoma and peripheral T cell lymphoma and are planning to open a trial in germ cell tumors as well.
• Inducible caspase 9 safety switch: We have CAR-T clinical trials using the inducible caspase 9 safety switch to mitigate life-threatening toxicities. We have a recent publication describing using the safety switch in one of our clinical trials.
• Solid Tumors: We are opening new trials with novel targets and approaches in solid tumors including a trial in GBM, lung cancer and head and neck cancers.

Multiple Myeloma and Amyloidosis Program

The UNC Lineberger Multiple Myeloma and Amyloidosis Program is a highly active clinical entity serving patients across NC and surrounding states with plasma cell disorders.  The program also hosts a robust research effort aimed at improving therapies for patients with these disorders worldwide by devising cutting edge new medications, optimizing existing ones, and otherwise studying methods for improving care for patients.

The program is primarily based at the UNC Hillsborough Medical Office Building. This geography affords our patients the best of both worlds – all the advances of a subspecialty academic medical center, with the comfort and convenience of a small clinic.

Broadly speaking in terms of research, the program has a number of scientific initiatives. A few examples follow.

Clinically developing new agents and optimizing existing agents for treating plasma cell disorders:

UNC Lineberger physicians lead national efforts advancing the treatment of these conditions.  Sam Rubinstein, MD MSCI is chairing an NC-wide study (LCCC2323) of daratumumab, lenalidomide, bortezomib and dexamethasone in patients with newly diagnosed myeloma, testing a novel “real world” schedule for administering these medications that is likely more tolerable and convenient than standard approaches.  The study is one of the first of its kind in the US to utilize a “decentralized model,” which broadens its availability statewide, in recognition of the desire of many patients to be treated close to home and not repeatedly travel to UNC for their myeloma care.  Eben Lichtman, MD is leading a national study (LCCC2119) of isatuximab, pomalidomide and dexamethasone in older and frail adults with relapsed and refractory multiple myeloma.  The standard dosing for this regimen can be difficult on patients who are vulnerable to side effects, and this study is testing a reduced-dosing strategy geared toward preserving the regimen’s effectiveness in controlling myeloma while reducing side effect burden.  Sascha Tuchman, MD MHS is the chair for a nationwide study (A062102) in patients with relapsed and refractory myeloma who have been treated with idecabtagene vicleucel (“Abecma”) CAR-T, and then receive either a new medication called iberdomide or standard observation.  The study’s goal is to assess the safety of iberdomide in these patients, as well as the drug’s ability to enhance CAR-T’s ability to keep myeloma in remission for a longer period of time. Separately, Dr. Tuchman also leads the LCCC1603 study of a new CD138-directed chimeric antigen receptor T-cell (CAR-T) for the treatment of advanced myeloma.  This is a truly bench-to-bedside UNC creation: it was designed in the lab by UNC faculty Drs. Barbara Savoldo and Gianpietro Dotti, it is manufactured for patients at clinical-grade (“GMP”) UNC facilities, and it is being studied in a first-in-human clinical trial for patients in the UNC clinical program who need newer approaches.  UNC Lineberger is one of very few centers worldwide that has the ability to take something like this from discovery all the way to patients.

Laboratory-based efforts to deepen our understanding of disease biology and develop entirely new approaches for therapy:

Eben Lichtman, MD created the LCCC1849 (PERMIT) study in collaboration with UNC infectious disease physician Tessa Andermann, MD, to examine both immune system function and the gut microbiome (bacteria and other organisms that naturally live in the intestines) in patients with plasma cell disorders.  1) In patients with myeloma precursor conditions (monoclonal gammopathy of uncertain significance or smoldering myeloma), they aim to identify immune or microbiome predictors of development of multiple myeloma.  2) For patients with smoldering myeloma or active multiple myeloma on treatment, they seek to explore the same domains to find predictors of response to therapy and longer duration of remission.  Better understanding these areas will hopefully lead to the development of concepts regarding how to intervene in these areas in ways that improve clinical outcomes for patients.

The entire program is collaborating with UNC Lineberger physician scientist Dr. Chad Pecot, who is an internationally renowned expert in RNA therapeutics.  The group is working with Dr. Pecot and his lab to create first-ever types of new RNA-based approaches for suppressing the synthesis of key proteins in myeloma development, with the aim of devising chemotherapy-free approaches to treating these disorders. Once appropriate candidates are identified, they will be moved forward into the UNC clinics where they will be offered as part of research studies to patients needing new approaches.

Clinical correlatives to better understand the impact of plasma cell disorders and treatment on patients:

The entire program collaborates to run the LCCC1728 study and the separate but connected UNC plasma cell disease quality database.  These efforts conducted among patients being treated at UNC for any plasma cell disorder collect data from patients in such areas as quality of life, physical function, cognitive function, response to therapy and financial impact of treatment. The goal of this now 300+ patient and 5+ year effort is two-fold: 1) to provide objective data that ensures that the quality of clinical care for patients with plasma cell disorders at UNC is outstanding, and 2) to provide research data that enables the program to learn from our patients’ experience.  Multiple manuscripts have been published in the scientific literature using these data, which means that people worldwide with multiple myeloma and related conditions are learning from our patients and our work.

The basic science and clinical studies that are carried out by hematology faculty cover a broad range of hematologic malignancies (the biology and treatment of hematologic cancers) and blood disorders.

Laboratory research is focused on several topics including: vascular biology and angiogenesis, tumor immunology, telomere dynamics, telomere function in stem cells and cancer, oncogene activation, the microbiome, crosstalk between blood clotting and inflammation, organoid models of human tumors, and aberrant stem cells in leukemia.

Clinical research centers on clinical trials of novel agents for the treatment of the broad range of blood disorders and corresponding translational studies. A major priority of the division is to translate the results of research from the laboratory into the clinic to provide new approaches for diagnosis and treatment of hematologic disorders.

Lorry Lokey Stem Cell Research Building

Center for Clinical Science Research

An official website of the United States government

Here’s how you know

Official websites use .gov A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

• Entire Site
• Research & Funding
• Health Information
• About NIDDK
• Research Programs & Contacts

Hematology Centers Program

Designed to increase access to critical research resources and collaboration in the national multidisciplinary research effort to combat nonmalignant hematologic diseases and to study normal hematopoiesis.

NIDDK Program Staff

• Shilpa Hattangadi, M.D. Epigenetics, hematopoiesis, and bone marrow failure
• Jenna Norton, Ph.D., M.P.H. Health equity, social determinants of health & health data standards

Funding for Hematology Centers

NIDDK funds Cooperative Centers of Excellence in Hematology via U54. The most recent funding opportunity is RFA-DK-19-005 . NIDDK funds a Hematology Central Coordinating Center via U24. The most recent funding opportunity is RFA-DK-19-013 .

Resources and Services Available from the Hematology Centers Program

The Hematology Central Coordinating Center (HCCC) provides central administrative and communications support for the NIDDK Hematology Centers Program and operates a Pilot and Feasibility Program, supporting pilot research studies that will lead to larger research projects.

• Research Aims: The overarching goal of these programs is to support and expand the national research effort to combat nonmalignant hematologic diseases and focus areas of hematopoiesis.
• Consortium Resources
• Pilot and Feasibility Program

Cooperative Centers of Excellence in Hematology

The Cooperative Centers of Excellence in Hematology (CCEH) generate investigative resources that can be made available to the broader research community. They involve integrated teams of investigators from a wide range of disciplines, share specialized equipment, and serve as regional or national resources. In additional to the national pilot and feasibility program managed by the HCCC, the CCEH may also support pilot and feasibility programs that fund small projects aimed to generate preliminary data for inclusion in larger grant applications as well as short-term enrichment activities.

The CCEH provide a focus for multidisciplinary investigations into gene structure and function; the cellular and molecular mechanisms involved in the production, maturation, and function of blood cells; and the development of strategies to treat nonmalignant hematologic diseases. The CCEH offer unique resources and established hematology expertise through scientific cores on a fee-for-service basis. Each Center has independent opportunities for enrichment activities.

The Hematology Centers Program operates as a consortium, comprised of the HCCC and several CCEH. This consortium is actively engaged to better serve the national hematology community, so visit the consortium website for new opportunities and the latest updates to the Cores.

Center Sites

Below are the currently funded Cooperative Centers of Excellence in Hematology. Please visit the consortium website for additional details.

• Research Aims: To apply novel technologies to understand blood cell development and diseases.
• Xenotransplant and Genome Editing Core
• Single Cell Characterization and Procurement Core
• Gene Delivery Core
• Enrichment Program
• Research Aims:  To advance research in stem cell and transplantation biology.
• Cell Procurement and Processing
• Cell Manipulation Tools
• Canine Disease Transplantation Model
• Research Aims:  To advance research in the regulation of human and murine hematopoiesis at the level of hematopoietic stem and progenitor cells.
• Experimental Mouse Resource Core
• Flow and Tissue Cytometry Core
• Hypoxia Core
• Research Aims:  To advance research in iron and heme disorders.
• Iron and Heme Core
• Metabolomics Core
• Protein-Metabolite Interactomics
• Research Aims:  To apply innovative, emerging technologies to normal and perturbed hematopoiesis.
• Cell Preparation and Analysis Core
• Imaging Core
• Animal Modeling Core

Related Links

• Porphyria Consortium  
• Center for Inherited Disease Research (CIDR)  
• ENCODE: Encyclopedia of DNA Elements
• VISION: ValIdated Systematic IntegratiON of hematopoietic epigenomes

View related clinical trials from ClinicalTrials.gov.

Study sections conduct initial peer review of applications in a designated scientific area. Visit the NIH’s Center for Scientific Review website to search for study sections.

Research Resources

NIDDK makes publicly supported resources, data sets, and studies available to researchers to accelerate the rate and lower the cost of new discoveries.

• Ancillary Studies to Major Ongoing Clinical Studies to extend our knowledge of the diseases being studied by the parent study investigators under a defined protocol or to study diseases and conditions not within the original scope of the parent study but within the mission of the NIDDK.
• NIDDK Central Repository for access to clinical resources including data and biospecimens from NIDDK-funded studies.
• NIDDK Information Network (dkNET) for simultaneous search of digital resources, including multiple datasets and biomedical resources relevant to the mission of the NIDDK.

Additional Research Programs

Research training.

NIDDK supports the training and career development of medical and graduate students, postdoctoral fellows, and physician scientists through institutional and individual grants.

Diversity Programs

The NIDDK offers and participates in a variety of opportunities for trainees and researchers from communities underrepresented in the biomedical research enterprise. These opportunities include travel and scholarship awards, research supplements, small clinical grants, high school and undergraduate programs, and a network of minority health research investigators.

Small Business

Small business programs.

NIDDK participates in the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. These programs support innovative research conducted by small businesses that has the potential for commercialization.

Human Subjects Research

NIDDK provides funding for pivotal clinical research, from preliminary clinical feasibility to large multi-center studies.

Translational Research

NIDDK provides funding opportunities and resources to encourage translation of basic discoveries into novel therapeutics.

Meetings & Workshops

Supports researchers with tools to enhance scientific rigor, reproducibility, and transparency, and provides a big data knowledge base for genomic and pathway hypothesis generation.

Providing education and training for the next generation of biomedical and behavioral scientist

Stay informed about the latest events, or connect through social media.

Learn about current projects and view funding opportunities sponsored by the NIH Common Fund .

Registration is required at eRA Commons and grants.gov and can take 4 weeks.

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma

Affiliations.

• 1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
• 2 Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
• 3 Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China.
• 4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. [email protected].
• 5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. [email protected].
• 6 Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China. [email protected].
• PMID: 37032379
• PMCID: PMC10083170
• DOI: 10.1038/s41392-023-01358-y

Genetic classification helps to disclose molecular heterogeneity and therapeutic implications in diffuse large B-cell lymphoma (DLBCL). Using whole exome/genome sequencing, RNA-sequencing, and fluorescence in situ hybridization in 337 newly diagnosed DLBCL patients, we established a simplified 38-gene algorithm (termed 'LymphPlex') based on the information on mutations of 35 genes and rearrangements of three genes (BCL2, BCL6, and MYC), identifying seven distinct genetic subtypes: TP53 Mut (TP53 mutations), MCD-like (MYD88, CD79B, PIM1, MPEG1, BTG1, TBL1XR1, PRDM1, IRF4 mutations), BN2-like (BCL6 fusion, NOTCH2, CD70, DTX1, BTG2, TNFAIP3, CCND3 mutations), N1-like (NOTCH1 mutations), EZB-like (BCL2 fusion, EZH2, TNFRSF14, KMT2D, B2M, FAS, CREBBP, ARID1A, EP300, CIITA, STAT6, GNA13 mutations, with or without MYC rearrangement), and ST2-like (SGK1, TET2, SOCS1, DDX3X, ZFP36L1, DUSP2, STAT3, IRF8 mutations). Extended validation of 1001 DLBCL patients revealed clinical relevance and biological signature of each genetic subtype. TP53 Mut subtype showed poor prognosis, characterized by p53 signaling dysregulation, immune deficiency, and PI3K activation. MCD-like subtype was associated with poor prognosis, activated B-cell (ABC) origin, BCL2/MYC double-expression, and NF-κB activation. BN2-like subtype showed favorable outcome within ABC-DLBCL and featured with NF-κB activation. N1-like and EZB-like subtypes were predominated by ABC-DLBCL and germinal center B-cell (GCB)-DLBCL, respectively. EZB-like-MYC + subtype was characterized by an immunosuppressive tumor microenvironment, while EZB-like-MYC - subtype by NOTCH activation. ST2-like subtype showed favorable outcome within GCB-DLBCL and featured with stromal-1 modulation. Genetic subtype-guided targeted agents achieved encouraging clinical response when combined with immunochemotherapy. Collectively, LymphPlex provided high efficacy and feasibility, representing a step forward to the mechanism-based targeted therapy in DLBCL.

© 2023. The Author(s).

Publication types

• Research Support, Non-U.S. Gov't
• Butyrate Response Factor 1 / genetics
• Immediate-Early Proteins* / genetics
• Immediate-Early Proteins* / therapeutic use
• In Situ Hybridization, Fluorescence
• Interleukin-1 Receptor-Like 1 Protein / genetics
• Lymphoma, Large B-Cell, Diffuse* / drug therapy
• NF-kappa B / genetics
• Proto-Oncogene Proteins c-bcl-2 / genetics
• Tumor Microenvironment
• Tumor Suppressor Proteins / genetics
• Interleukin-1 Receptor-Like 1 Protein
• Proto-Oncogene Proteins c-bcl-2
• ZFP36L1 protein, human
• Butyrate Response Factor 1
• BTG2 protein, human
• Immediate-Early Proteins
• Tumor Suppressor Proteins